Loading organizations...
§ Private Profile · Guangzhou, Guangdong, China
Develops and sells noninvasive early cancer screening products and tumor diagnostics for hospitals in China.
Creative Biosciences is a biomedical diagnostics company based in Guangzhou, China, that develops and manufactures noninvasive early cancer screening products, including the Colosafe stool DNA test for colorectal cancer. The company operates with an estimated 21 to 50 employees and has successfully implemented its tumor diagnostic kits and related automation equipment in over 700 major hospitals across mainland China. Generating an estimated annual revenue of $7.8 million with an estimated valuation of $25 million, the firm currently holds seven filed patents for its point of care testing technologies. Creative Biosciences has raised a total of $234.15 million in venture capital funding across multiple rounds, securing financial backing from prominent institutional investors including IDG Capital, CDH Investments, Tsing Song Capital, and YuanBio Venture Capital. The diagnostic healthcare organization was officially founded in 2015 by lead executive Hongzhi Zou.
Creative Biosciences has raised $87.9M across 1 funding round.
Creative Biosciences has raised $87.9M in total across 1 funding round.
Creative Biosciences has raised $87.9M across 1 funding round. Most recently, it raised $87.9M Series C in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 27, 2020 | $87.9M Series C | — | CDH Investments, IDG Capital, Oceanpine Capital, Shengyu Investment | Announced |
Creative Biosciences has raised $87.9M in total across 1 funding round.
Creative Biosciences's investors include CDH Investments, IDG Capital, Oceanpine Capital, Shengyu Investment.